A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Trial Profile

A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Varlilumab (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 18 Apr 2017 Planned End Date changed from 1 Mar 2019 to 1 Sep 2017.
    • 18 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2017.
    • 15 Mar 2017 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top